Abstract:Key PointsNotable heterogeneity exists in the neuropathological substrates that underlie dementia in the setting of Parkinson's disease dementia (PDD). Nevertheless, the presumptive caudal-to-rostral spread of Lewy body and neurite pathology from the lower brainstem to telencephalic regions, which culminates in a heavy burden of this α-synuclein (α-syn) pathology in limbic and neocortical structures, is the most characteristic pathological finding in most PDD cases.Up to 50% of patients with PDD can have sufficient amyloid-β (Aβ) plaque and tau neurofibrillary tangle (NFT) pathology for the diagnosis of a second neurodegenerative dementia — that is, Alzheimer's disease (AD) — and this co-morbid pathology is more common in PDD than PD.Tau NFT and Aβ plaque pathology may act synergistically with Lewy body and neurite pathology to confer a worse prognosis and a higher burden of cortical Lewy body and neurite pathology in PDD.Clinical phenotypes of PD may help to identify neuropathological subtypes of PD that exhibit differing propensities for developing dementia. For example, non-tremor-dominant or postural gait instability PD phenotypes may often be associated with greater Aβ plaque pathology and shorter times to dementia in patients with PDD than in patients with PD exhibiting less co-morbid AD neuropathology and a tremor-dominant phenotype.Genetic variations may contribute to the heterogeneity in the neuropathology and the time-of-onset of dementia in PD. For example, the apolipoprotein E (APOE) ε4 genotype may increase both Lewy body and neurite pathology and AD neuropathology and result in an increased risk of dementia in PD. Moreover, heterozygous mutations in β-glucocerebrosidase (GBA) may increase the severity of Lewy body and neurite patholgy in 'pure' synucleinopathies.Further biomarker and detailed clinicopathological correlation studies of prospective patients will help to further elucidate the inter-relationships of AD and α-syn pathology in PD and the development of dementia in patients with PD. These discoveries will be crucial in the development of meaningful disease-modifying therapies for PDD.

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies